iRadimed (IRMD) Stock Price, News & Analysis

Company Overview

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on equipment that enables clinicians to provide continuous care and monitor patients safely while they are undergoing MRI procedures, where conventional medical devices may pose safety or compatibility challenges.

Its product portfolio includes the MRidium MRI-compatible infusion pump systems, which are designed to deliver intravenous medications and fluids during MRI examinations, as well as MRI-compatible patient monitoring systems and related accessories. These products are intended for use in areas such as anesthesia, critical care, emergency medicine and diagnostic imaging.

Founded in 2004 and headquartered in Orlando, Florida, iRadimed serves hospitals, imaging centers and other healthcare providers in the United States and international markets through a combination of direct sales and distributors. The company was founded by Roger Susi, who has served as its president and chief executive officer.

Key Stats

• Today's Range: $85.69 to $87.91
• 50-Day Range: $81.87 to $97.77
• 52-Week Range: $67.84 to $107.90
• Volume: 164,104 shs
• Average Volume: 114,241 shs
• Market Capitalization: $1.10 billion
• P/E Ratio: 48.24
• Dividend Yield: 0.93%
• Price Target: $120.00
• Consensus Rating: Moderate Buy

iRadimed Stock Analysis - MarketRank™

iRadimed scored higher than 54% of companies evaluated by MarketBeat, and ranked 426th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

iRadimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

iRadimed has a consensus price target of $120.00, representing about 39.0% upside from its current price of $86.35.

Amount of Analyst Coverage

iRadimed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iRadimed is 48.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRadimed is 48.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.

Price to Book Value per Share Ratio

iRadimed has a P/B Ratio of 11.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.34% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 8.38.

Change versus previous month

Short interest in iRadimed has recently decreased by 4.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

iRadimed has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

iRadimed has only been increasing its dividend for 1 years.

Dividend Coverage

The dividend payout ratio of iRadimed is 44.69%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for iRadimed this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added iRadimed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,616.00 in company stock.

Percentage Held by Insiders

34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/31/2026
• Record date for 8/28 Dividend: 8/14/2026
• Ex-Dividend for 8/28 Dividend: 8/14/2026
• Dividend Payable: 8/28/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:IRMD
• CIK: 1325618
• Web: www.iradimed.com
• Phone: (407) 677-8022
• Fax: 407-677-5037
• Employees: 166
• Year Founded: 2004

Price Target and Rating

• Average Price Target for iRadimed: $120.00
• High Price Target: $120.00
• Low Price Target: $120.00
• Potential Upside/Downside: +39.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.79
• Trailing P/E Ratio: 48.24
• Forward P/E Ratio: 43.61
• P/E Growth: N/A
• Net Income: $22.48 million
• Net Margins: 26.70%
• Pretax Margin: 34.45%
• Return on Equity: 23.45%
• Return on Assets: 20.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.46
• Quick Ratio: 8.13

Sales & Book Value

• Annual Sales: $83.81 million
• Price / Sales: 13.18
• Cash Flow: $1.86 per share
• Price / Cash Flow: 46.54
• Book Value: $7.44 per share
• Price / Book: 11.61

Miscellaneous

• Outstanding Shares: 12,790,000
• Free Float: 8,363,000
• Market Cap: $1.10 billion
• Optionable: Optionable
• Beta: 0.89